Subbu Nabi's questions to Grail Inc (GRAL) leadership • Q4 2024
Question
An associate on behalf of Subbu Nabi inquired about the definition of success for the PATHFINDER 2 study, asking about key endpoints and performance expectations. A follow-up question sought any new details on the company's long-term cash position.
Answer
President Dr. Joshua Ofman explained that PATHFINDER 2's success will be measured by traditional test performance metrics like specificity, sensitivity, and predictive values, as well as safety measures. He noted the results will be part of the final modular PMA submission to the FDA in the first half of 2026. CFO Aaron Freidin reiterated that there is no change to the company's cash runway, which extends into 2028, following the restructuring completed in 2024.